当前位置： SCI文献检索 > Targeted Oncology期刊下所有文献 > A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma.

A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma.

Abstract：

:The discovery of chemoresistant cancer stem cells (CSCs) in carcinomas has created the need for therapies that specifically target these subpopulations of cells. Here, we characterized a bispecific targeted toxin that is composed of two antibody fragments and a catalytic protein toxin allowing it to bind two CSC markers on the same cell killing this resistant subpopulation. CD133 is a well-known CSC marker and has been successfully targeted and caused regression of head and neck squamous cell carcinoma (HNSCC) in vivo. To enable it to bind a broader range of CSCs, an anti-epithelial cell adhesion molecule (EpCAM) scFv was added to create dEpCAMCD133KDEL, a deimmunized bispecific targeted toxin on a single amino acid chain. This bispecific potently inhibited protein translation and proliferation in vitro in three different types of carcinoma. Furthermore, in a CSC spheroid model dEpCAMCD133KDEL eliminated Mary-X spheroids, an inflammatory breast carcinoma. Finally, this bispecific also caused tumor regression in an in vivo model of HNSCC. This represents the first bispecific CSC-targeted toxin and warrants further development as a possible therapy for carcinoma.

journal_name

Target Oncol

journal_title

Targeted oncology

authors

Waldron NN,Barsky SH,Dougherty PR,Vallera DA

doi

10.1007/s11523-013-0290-9

subject

Has Abstract

pub_date

2014-09-01 00:00:00

pages

239-49

issue

3

eissn

1776-2596

issn

1776-260X

journal_volume

9

pub_type

杂志文章

相关文献

Targeted Oncology文献大全
  • Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance.

    abstract：:The poly(ADP-ribose) polymerase inhibitor rucaparib is approved as monotherapy in the treatment and maintenance settings for women with relapsed ovarian cancer in the European Union and the United States. We review the safety profile of rucaparib in both settings and provide recommendations for the clinical management...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-020-00715-z

    authors： Lorusso D,García-Donas J,Sehouli J,Joly F

    更新日期：2020-06-01 00:00:00

  • Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.

    abstract：BACKGROUND:Immunotherapy based on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients with high PD-L1 expression or DNA mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) cancer are re...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-020-00703-3

    authors： Huang D,Zhang F,Tao H,Zhang S,Ma J,Wang J,Liu Z,Cui P,Chen S,Huang Z,Wu Z,Zhao L,Hu Y

    更新日期：2020-02-01 00:00:00

  • Hyperbaric oxygen therapy and cancer--a review.

    abstract：:Hypoxia is a critical hallmark of solid tumors and involves enhanced cell survival, angiogenesis, glycolytic metabolism, and metastasis. Hyperbaric oxygen (HBO) treatment has for centuries been used to improve or cure disorders involving hypoxia and ischemia, by enhancing the amount of dissolved oxygen in the plasma a...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-012-0233-x

    authors： Moen I,Stuhr LE

    更新日期：2012-12-01 00:00:00

  • Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC.

    abstract：:Atezolizumab (Tecentriq®), a humanized, anti-programmed cell death ligand-1 (PD-L1) monoclonal antibody, in combination with bevacizumab, carboplatin and paclitaxel (ABCP) or with carboplatin and nab-paclitaxel (ACnP) has been approved as first-line treatment for metastatic nonsquamous NSCLC, based on results from the...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-019-00686-w

    authors： Dhillon S,Syed YY

    更新日期：2019-12-01 00:00:00

  • Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.

    abstract：:Elderly and poor performance status advanced non-small cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib and gefitinib, are active agents in the t...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-009-0104-2

    authors： Lin CC,Yang CH

    更新日期：2009-01-01 00:00:00

  • Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor.

    abstract：:In subsets of gastrointestinal stromal tumors (GISTs), mutations of the KIT and PDGFRA receptor tyrosine kinases correlate with tumor prognosis and response to tyrosine kinase inhibitors (TKIs). Determining genotypes in TKI-resistant GISTs is challenging due to the potential risks and limitations of repeated biopsies ...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-015-0361-1

    authors： Kang G,Bae BN,Sohn BS,Pyo JS,Kang GH,Kim KM

    更新日期：2015-12-01 00:00:00

  • Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice.

    abstract：:The advent of imatinib mesilate, an oral target therapy, has dramatically changed the natural history of gastrointestinal stromal tumours (GISTs). This rare neoplasm has become the paradigm of targeted therapies in solid tumours, also introducing a home-based cure concept in oncology. However, it should be retained th...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-012-0221-1

    authors： Saponara M,Pantaleo MA,Nannini M,Biasco G

    更新日期：2012-12-01 00:00:00

  • EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.

    abstract：:Basal transcription regulation of the epidermal growth factor receptor is dependent upon a CA simple sequence repeat polymorphism in the intron-1 (CA-SSR-1). Here, we evaluate the role of CA-SSR-1 in complete resected esophageal cancer (EC) patients without neoadjuvant or adjuvant treatment. Genomic DNA was extracted ...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-013-0260-2

    authors： Vashist YK,Trump F,Gebauer F,Kutup A,Güngör C,Kalinin V,Muddasar R,Vettorazzi E,Yekebas EF,Brandt B,Pantel K,Izbicki JR

    更新日期：2014-03-01 00:00:00

  • Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.

    abstract：BACKGROUND:The WEE1 inhibitor adavosertib (AZD1775) has been investigated in Western patients. OBJECTIVE:This open-label Phase Ib study (NCT02341456) investigated the safety, pharmacokinetics, and clinical activity of adavosertib in combination with carboplatin alone or paclitaxel plus carboplatin in Asian patients wi...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-020-00701-5

    authors： Kato H,de Souza P,Kim SW,Lickliter JD,Naito Y,Park K,Kumar S,Mugundu GM,Bang YJ

    更新日期：2020-02-01 00:00:00

  • Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.

    abstract：BACKGROUND:A consistent percentage of patients with metastatic non-small cell lung cancer (NSCLC) derives no or only marginal benefit from immunotherapy (IO). OBJECTIVE:Since serum sodium has been linked to both prognosis in NSCLC and modulation of immune cells activity, we aimed to assess the association between low ...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-018-0599-5

    authors： Fucà G,Galli G,Poggi M,Lo Russo G,Proto C,Imbimbo M,Vitali M,Ganzinelli M,Lanti C,Molino G,Stangoni F,Zilembo N,de Braud F,Garassino MC,Signorelli D

    更新日期：2018-12-01 00:00:00

  • Delta-catenin promotes the proliferation and invasion of colorectal cancer cells by binding to E-cadherin in a competitive manner with p120 catenin.

    abstract：:δ-Catenin is the only member of the p120 catenin (p120ctn) subfamily whose normal pattern of expression is restricted to the brain. Similar to p120ctn, δ-catenin can bind to the juxtamembrane domain of E-cadherin. We examined the expression of δ-catenin, p120ctn, and E-cadherin using immunohistochemistry in 95 cases o...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-013-0269-6

    authors： Zhang H,Dai SD,Zhang D,Liu D,Zhang FY,Zheng TY,Cui MM,Dai CL

    更新日期：2014-03-01 00:00:00

  • The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities.

    abstract：:The influence of tumor infiltrating lymphocytes on tumor growth and response to therapy is becoming increasingly apparent. While much work has focused on the role of T cell responses in anti-tumor immunity, the role of B cells in solid tumors is much less understood. Tumor infiltrating B cells have been found in a var...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-017-0481-x

    authors： Flynn NJ,Somasundaram R,Arnold KM,Sims-Mourtada J

    更新日期：2017-04-01 00:00:00

  • Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.

    abstract：BACKGROUND:Axitinib, an inhibitor of vascular endothelial growth factor (VEGF) receptors, is approved as second-line treatment for advanced renal cell carcinoma (RCC). Agents targeting the VEGF pathway may induce renal toxicities, which may be influenced by pre-existing renal dysfunction. OBJECTIVE:The objective was t...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-015-0389-2

    authors： Chen Y,Rini BI,Motzer RJ,Dutcher JP,Rixe O,Wilding G,Stadler WM,Tarazi J,Garrett M,Pithavala YK

    更新日期：2016-04-01 00:00:00

  • Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors.

    abstract：BACKGROUND:Immune checkpoint inhibitors (ICIs) demonstrated improved overall survival (OS) in heavily pretreated unselected patients with metastatic gastro-esophageal junction (mGOJ)/gastric cancer (GC). Attempts to select patients based on programmed death-ligand 1 (PD-L1) expression appear to be suboptimal. A strong ...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-020-00723-z

    authors： Formica V,Morelli C,Patrikidou A,Murias C,Butt S,Nardecchia A,Lucchetti J,Renzi N,Shiu KK,Roselli M,Arkenau HT

    更新日期：2020-06-01 00:00:00

  • Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study.

    abstract：BACKGROUND:The prognosis of patients with advanced pancreatic cancer is dismal, and there is a need for novel and effective treatments. OBJECTIVES:Tο determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of a novel gemcitabine (G) and temsirolimus (T) combination (phase I) and estimate the 6-m...

    journal_title：Targeted oncology

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s11523-018-0605-y

    authors： Karavasilis V,Samantas E,Koliou GA,Kalogera-Fountzila A,Pentheroudakis G,Varthalitis I,Linardou H,Rallis G,Skondra M,Papadopoulos G,Papatsibas G,Sgouros J,Goudopoulou A,Kalogeras KT,Dervenis C,Pectasides D,Fountzilas G

    更新日期：2018-12-01 00:00:00

  • Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.

    abstract：:Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) catalyze the first rate-limiting step in the oxidative metabolism of compounds containing indole rings, including the transformation of the essential amino acid L-tryptophan to N-formyl-L-kynurenine. Through direct and indirect means, IDO exerts bo...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-017-0547-9

    authors： Davar D,Bahary N

    更新日期：2018-04-01 00:00:00

  • Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24).

    abstract：BACKGROUND:The variability in progression-free survival (PFS) and overall survival (OS) among patients with epithelial ovarian cancer (EOC) makes it difficult to reliably predict outcomes. A predictive biomarker of bevacizumab efficacy as first-line therapy in EOC is still lacking. OBJECTIVE:The MITO group conducted a...

    journal_title：Targeted oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s11523-018-0574-1

    authors： Farolfi A,Petrone M,Scarpi E,Gallà V,Greco F,Casanova C,Longo L,Cormio G,Orditura M,Bologna A,Zavallone L,Ventriglia J,Franzese E,Loizzi V,Giardina D,Pigozzi E,Cioffi R,Pignata S,Giorda G,De Giorgi U

    更新日期：2018-08-01 00:00:00

  • Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial.

    abstract：:The First-Line Erbitux in Lung Cancer (FLEX) trial showed that the addition of cetuximab to chemotherapy followed by weekly cetuximab maintenance significantly improved survival in the first-line treatment of advanced non-small cell lung cancer (NSCLC). The phase IIIb NSCLC Erbitux Trial (NEXT) trial (NCT00820755) inv...

    journal_title：Targeted oncology

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s11523-014-0336-7

    authors： Heigener DF,Pereira JR,Felip E,Mazal J,Manzyuk L,Tan EH,Merimsky O,Sarholz B,Esser R,Gatzemeier U

    更新日期：2015-06-01 00:00:00

  • Targeting insulin-like growth factor type 1 receptor in cancer therapy.

    abstract：:It is believed that the insulin-like growth factor receptor type 1 (IGF-1R) signaling pathway plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies. Strategies are being developed to block IGF-1R as an anticancer treatment. We reviewed several potential strategies for disrupting th...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-009-0123-z

    authors： Atzori F,Traina TA,Ionta MT,Massidda B

    更新日期：2009-12-01 00:00:00

  • Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment.

    abstract：:Dynamic contrast-enhanced ultrasonography (DCE-US) is a new functional technique enabling a quantitative assessment of solid tumor perfusion using raw linear data. DCE-US allows the calculation of parameters as slope of wash-in or area under the curve (AUC) representing, respectively, blood flow or blood volume. Reduc...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-010-0136-7

    authors： Lassau N,Chebil M,Chami L,Bidault S,Girard E,Roche A

    更新日期：2010-03-01 00:00:00

  • Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series.

    abstract：:Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive malignancy with poor outcome occurring in adolescents and young adults. Therapeutic options for patients with advanced disease are limited. Preclinical studies have shown that VEGFR-2 and VEGFA are overexpressed in DSRCT and that DSRCT xenografts wer...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-012-0251-8

    authors： Italiano A,Kind M,Cioffi A,Maki RG,Bui B

    更新日期：2013-09-01 00:00:00

  • Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma.

    abstract：:Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotox...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-016-0452-7

    authors： Swamy SG,Kameshwar VH,Shubha PB,Looi CY,Shanmugam MK,Arfuso F,Dharmarajan A,Sethi G,Shivananju NS,Bishayee A

    更新日期：2017-02-01 00:00:00

  • Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy.

    abstract：BACKGROUND:In 2017, nivolumab monotherapy was shown to be effective as third- or later-line therapy in patients with advanced gastric or gastroesophageal junction cancer. OBJECTIVE:In this study, we investigated the relationship between the neutrophil-to-lymphocyte ratio (NLR) and the outcomes of nivolumab monotherapy...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-020-00716-y

    authors： Yamada T,Hayashi T,Inokuchi Y,Hayashi K,Watanabe H,Komori K,Kano K,Shimoda Y,Fujikawa H,Shiozawa M,Morinaga S,Rino Y,Masuda M,Ogata T,Oshima T

    更新日期：2020-06-01 00:00:00

  • Identification of driver mutations in lung cancer: first step in personalized cancer.

    abstract：:Non-small cell lung cancer (NSCLC) has recently been associated with interesting molecular characteristics that have important implications in carcinogenesis and response to targeted therapies. Targeted therapies, if given to a patient subpopulation enriched by the presence of relevant molecular targets, can often abr...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-013-0263-z

    authors： Planchard D

    更新日期：2013-03-01 00:00:00

  • Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial.

    abstract：:Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Efficacy of this drug was documented in the BR.21 trial showing that adenocarcinoma, female gender, Asian ethnicity and never-smoker status are predictive of clinical response to erlotinib. Retrospective studies documented the same bene...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-010-0163-4

    authors： Rossi D,Dennetta D,Ugolini M,Catalano V,Alessandroni P,Giordani P,Baldelli AM,Casadei V,Graziano F,Luzi Fedeli S

    更新日期：2010-12-01 00:00:00

  • Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.

    abstract：:Several angiogenesis inhibitors have been approved for commercial use and many additional agents are under development for the treatment of various malignancies. Cardiovascular toxicities have been increasingly recognized as effects of this entire class of new anticancer therapeutics. There is a limited but growing un...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-009-0106-0

    authors： Snider KL,Maitland ML

    更新日期：2009-04-01 00:00:00

  • Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.

    abstract：:ABP 980 was developed as a biosimilar to trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), that is indicated for the treatment of HER2-positive metastatic breast cancer, early breast cancer (EBC), and metastatic gastric cancer. ABP 980 is approved in the United States, Europ...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-019-00675-z

    authors： Kolberg HC,Colleoni M,Santi P,Demetriou GS,Segui-Palmer MA,Fujiwara Y,Hurvitz SA,Hanes V

    更新日期：2019-12-01 00:00:00

  • Targeted therapies in thyroid cancer.

    abstract：:Differentiated thyroid carcinoma is the most frequent neoplasm of the endocrine system. Although thyroid cancer usually has an excellent prognosis, no therapeutic options are available for patients that develop metastases and are or became resistant to radioiodine therapy. The deeper knowledge of molecular aberrations...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-009-0124-y

    authors： Capdevila J,Perez-Garcia J,Obiols G,Tabernero J

    更新日期：2009-12-01 00:00:00

  • Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.

    abstract：:Venetoclax (Venclyxto®; Venclexta®) is a first-in-class, oral, selective B cell lymphoma-2 (BCL-2) inhibitor. The drug is approved in numerous countries, including those of the EU and in the USA, for the treatment of adults with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL); the specific indication(s)...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-019-00673-1

    authors： Scott LJ

    更新日期：2019-10-01 00:00:00

  • Impact of biomarkers on non-small cell lung cancer treatment.

    abstract：:Chemotherapy represents the mainstay of non-small cell lung cancer (NSCLC) treatment, but response is usually observed in only one out of three patients. Massive efforts have been carried out to identify biomarkers that might help clinicians to choose appropriate drugs, by identifying potentially sensitive subjects an...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-010-0132-y

    authors： Toschi L,Cappuzzo F

    更新日期：2010-03-01 00:00:00